Ligand Pharmaceuticals Incorporated
NASDAQ:LGNDBiotechnology
+$2.89 today
- Market cap
- $5.98B
- Beta
- 1.04
- P/E (TTM)
- 34.4
- EPS (TTM)
- $7.72
Volume 0.38M
Average 0.22M
LGND Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Ligand Pharmaceuticals IncorporatedNASDAQ: LGND
Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Free cash flow grows, but more slowly than its trailing trend
Q2 FY2026 free cash flow of $23.99M rose 54.0% year over year, behind the +229.2% change in trailing-twelve-month free cash flow. Sequentially, it fell 50.5% from the prior quarter. Over 3 fiscal years it compounded at -25.8% a year.
Context
- Free cash flow amounted to 18.2% of revenue in FY2025, down 28.1 pp from a year earlier.
- Free cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +54.0% toward the trailing-twelve-month pace of +229.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 48.91M USD
- Year-over-year change
- -36.8%
- 4-year CAGR
- -8.6%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 48.91M | -36.8% |
| FY2024 | 2024-12-31 | 77.41M | +1912.0% |
| FY2023 | 2023-12-31 | (4.27M) | -103.6% |
| FY2022 | 2022-12-31 | 119.93M | +71.2% |
| FY2021 | 2021-12-31 | 70.04M | — |
Free Cash Flow vs competitors
How LGND compares with its peers on the latest reported figures
- LGND's LTM Jun 2026 free cash flow of $131.37M is the 9th largest of the 10 companies compared; the peer median is $1.92B.
- Its year-over-year change of +229.2% is the 2nd highest of 9, against a peer median of +30.0%.
- Free cash flow amounts to 45.2% of revenue for LGND, versus a peer median of 26.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $18.21B | -0.2% | -9.8% | 28.3% | |
| LTM Jun 2026 | $11.44B | -21.5% | +2.4% | 23.3% | |
| LTM Jun 2026 | $10.99B | -11.7% | -29.6% | 17.2% | |
| LTM Jun 2026 | $10.18B | -4.1% | -2.7% | 26.7% | |
| LTM Jun 2026 | $1.92B | +100.4% | +14.9% | 33.0% | |
| LTM Jul 2026 | $1.16B | +60.2% | +55.6% | 47.5% | |
| LTM Jun 2026 | $867.34M | — | -31.6% | 21.0% | |
| LTM Jun 2026 | $357.11M | +2165.8% | — | 38.0% | |
| LTM Jun 2026 | $131.37M | +229.2% | -25.8% | 45.2% | |
| LTM Mar 2026 | $79.27M | +124.4% | — | 26.4% | |
| Peer median (excluding LGND) | $1.92B | +30.0% | -2.7% | 26.7% | |
Competitors are the stored peer set for LGND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 57.14M | (33.36M) | 52.15M | (4.03M) | 124.45M |
| Depreciation & Amortization | 50.95M | 43.39M | 36.52M | 35.24M | 33.78M |
| Deferred Income Tax | (8.62M) | 20.72M | 11.7M | (15.8M) | 22.68M |
| Stock-Based Compensation | 38.78M | 60.29M | 25.74M | 41.09M | 0 |
| Change in Working Capital | (52.16M) | 65.68M | (34.4M) | 19.36M | (12.67M) |
| Accounts Receivables | (28.62M) | 55.32M | (2.6M) | (6.46M) | (21.74M) |
| Inventory | (427K) | 12.06M | (10.87M) | 9.62M | 4.99M |
| Accounts Payables | (1.17M) | (3.34M) | (4.7M) | 0 | 5.88M |
| Other Working Capital | (21.96M) | 1.64M | (16.23M) | 16.2M | (1.8M) |
| Other Non-Cash Items | (7.29M) | (18.87M) | (42.14M) | 21.2M | (118.89M) |
| Operating Cash Flow | 78.8M | 137.85M | 49.58M | 97.05M | 49.36M |
| Capital Expenditures | (8.76M) | (17.92M) | (53.85M) | (19.64M) | (452K) |
| Acquisitions (Net) | 494K | (750K) | (25.65M) | (172.19M) | (8.09M) |
| Purchases of Investments | (181.33M) | (51.23M) | (126.76M) | (226.38M) | (730.86M) |
| Sales of Investments | 221.34M | 234.39M | 194.17M | 269.62M | 377.28M |
| Other Investing Activities | (1.22M) | (868K) | (49.91M) | (12.89M) | (4.34M) |
| Investing Cash Flow | 30.52M | 163.62M | (11.68M) | (143.66M) | (377.32M) |
| Debt Repayment | (146.01M) | (260.8M) | (76.9M) | (25K) | 338.11M |
| Common Stock Issued | 33.76M | 3.23M | 22.45M | 37.14M | 114.89M |
| Common Stock Repurchased | (18.45M) | 0 | 0 | 0 | (15M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.07M) | (18.42M) | (5.5M) | 60.03M | (9.77M) |
| Financing Cash Flow | (137.76M) | (275.99M) | (59.95M) | 97.14M | 428.22M |
| Effect of Forex Changes | 0 | 0 | 0 | (1.17M) | 2.36M |
| Net Change in Cash | (28.44M) | 25.48M | (22.05M) | 49.35M | 102.62M |
| Free Cash Flow | 70.04M | 119.93M | (4.27M) | 77.41M | 48.91M |
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
Intrinsic Alpha fair value
Locked
Current Price
$298.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.